CoChat
Sign Up
Cited by 165Nanoplatforms for cancer theranosticsPhotodynamic Therapy Research StudiesCancer Immunotherapy and Biomarkers

Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation

Open access
Zhou, Yaxin, Ren, Xiaomeng, Hou, Zhaosheng, Wang, Ningning, Jiang, Yue, Luan, Yuxia·2021·Nanoscale Horizons
DOI 10.1039/d0nh00480d
Open this paper in CoChat — free accountOpen PDF

Abstract

A photosensitizer-based nanoplatform demonstrated amplified photodynamic immunotherapy by tumor microenvironment modulation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/d0nh00480d

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Hypoxic conditions in the tumor microenvironment and improper blood supply to the tumor mass present as a major barrier in clinical progress of photodynamic therapy.

    “However, the hypoxic conditions in the tumor microenvironment and improper blood supply to the tumor mass present as a major barrier in the clinical progress of this physical therapy [118].”

    From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [118]

  • Various research groups have contributed to EPR effect enhancement by physical means such as mild hyperthermia, photodynamic activation, radiation therapy, and ultrasounds.

    “Various research groups have contributed to the EPR effect enhancement strategies by employing physical means such as mild hyperthermia, photodynamic activation of tissues, radiation therapy, and ultrasounds [90,113,114,115,116,117,118,119].”

    From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [118]

    The Results and discussion section (page unavailable) attributes greater tumor accumulation of the nanoplatform partly to the EPR effect, but does not say that photodynamic activation enhances that effect. The Introduction describes laser-activated photodynamic therapy, not a physical strategy for EPR enhancement. Searches for mild hyperthermia, radiation therapy, and ultrasound found no passage addressing their use to enhance EPR. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 56

  1. [1]1. S. Z. F. Phua, G. Yang, W. Q. Lim, A. Verma, H. Chen, T. Thanabalu and Y. Zhao, ACS Nano, 2019, 13, 4742-4751.
  2. [2]2. D. Dolmans, D. Fukumura and R. K. Jain, Nat. Rev. Cancer, 2003, 3, 380-387.
  3. [3]3. J. X. Fan, M. D. Liu, C. X. Li, S. Hong, D. W. Zheng, X. H. Liu, S. Chen, H. Cheng and X. Z. Zhang, Nanoscale Horiz., 2017, 2, 349-355.
  4. [4]4. X. Li, S. Lee and J. Yoon, Chem. Soc. Rev., 2018, 47, 1174-1188.
  5. [5]5. A. P. Castano, T. N. Demidova and M. R. Hamblin, Photodiagn. Photodyn. Ther., 2005, 2, 91-106.
  6. [6]6. X. Duan, C. Chan and W. Lin, Angew. Chem., Int. Ed., 2019, 58, 670-680.
  7. [7]7. A. P. Castano, P. Mroz and M. R. Hamblin, Nat. Rev. Cancer, 2006, 6, 535-545.
  8. [8]8. Q. Li, D. Zhang, J. Zhang, Y. Jiang, A. Song, Z. Li and Y. Luan, Nano Lett., 2019, 19, 6647-6657.
  9. [9]9. J. H. Li, Y. Liu, X. N. Li, G. F. Liang, C. S. Ruan and K. Y. Cai, Nanoscale Horiz., 2020, 5, 350-358.
  10. [10]10. Q. Chen, L. Feng, J. Liu, W. Zhu, Z. Dong, Y. Wu and Z. Liu, Adv. Mater., 2016, 28, 7129-7136.
  11. [11]11. G. L. Semenza, Nat. Rev. Cancer, 2003, 3, 721-732.
  12. [12]12. D. Y. Zhao, W. H. Tao, S. H. Li, L. X. Li, Y. X. Sun, G. T. Li, G. Wang, Y. Wang, B. Lin, C. Luo, Y. J. Wang, M. S. Cheng, Z. G. He and J. Sun, Nanoscale Horiz., 2020, 5, 886-894.
  13. [13]13. G. Bergers and L. E. Benjamin, Nat. Rev. Cancer, 2003, 3, 401-410.
  14. [15]15. P. Carmeliet and R. K. Jain, Nature, 2000, 407, 249-257.
  15. [16]16. R. K. Jain, Science, 2005, 307, 58-62.
  16. [17]17. Y. Huang, B. Y. S. Kim, C. K. Chan, S. M. Hahn, I. L. Weissman and W. Jiang, Nat. Rev. Immunol., 2018, 18, 195-203.
  17. [18]18. Y. Huang, S. Goel, D. G. Duda, D. Fukumura and R. K. Jain, Cancer Res., 2013, 73, 2943-2948.
  18. [19]19. R. K. Jain, Cancer Cell, 2014, 26, 605-622.
  19. [20]20. D. S. Chen and I. Mellman, Immunity, 2013, 39, 1-10.
  20. [21]21. P. S. Hegde, J. J. Wallin and C. Mancao, Semin. Cancer Biol., 2018, 52, 117-124.
  21. [22]22. R. Ganss, B. Arnold and G. J. Hammerling, Eur. J. Immunol., 2004, 34, 2635-2641.
  22. [23]23. G. T. Motz and G. Coukos, Immunity, 2013, 39, 61-73.
  23. [24]24. J. Wada, H. Suzuki, R. Fuchino, A. Yamasaki, S. Nagai, K. Yanai, K. Koga, M. Nakamura, M. Tanaka, T. Morisaki and M. Katano, Anticancer Res., 2009, 29, 881-888.
  24. [25]25. H. Laubli, P. Mueller, L. D'Amico, M. Buchi, A. S. Kashyap and A. Zippelius, Cancer Immunol. Immunother., 2018, 67, 815-824.
  25. [26]26. D. I. Gabrilovich, H. L. Chen, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh and D. P. Carbone, Nat. Med., 1996, 2, 1096-1103.
  26. [27]27. N. G. Gavalas, M. Tsiatas, O. Tsitsilonis, E. Politi, K. Ioannou, A. C. Ziogas, A. Rodolakis, G. Vlahos, N. Thomakos, D. Haidopoulos, E. Terpos, A. Antsaklis, M. A. Dimopoulos and A. Bamias, Br. J. Cancer, 2012, 107, 1869-1875.
  27. [28]28. S. Loeb, A. Koenigsrainer, H. G. Rammensee, G. Opelz and P. Terness, Nat. Rev. Cancer, 2009, 9, 445-452.
  28. [29]29. G. C. Prendergast, C. Smith, S. Thomas, L. Mandik-Nayak, L. Laury-Kleintop, R. Metz and A. J. Muller, Cancer Immunol. Immunother., 2014, 63, 721-735.
  29. [30]30. D. H. Munn and A. L. Mellor, Trends Immunol., 2016, 37, 193-207.
  30. [31]31. S. S. Y. Lee, J. Li, J. N. Tai, T. L. Ratliff, K. Park and J. X. Cheng, ACS Nano, 2015, 9, 2420-2432.
  31. [32]32. Y. Gou, Y. Zhang, J. Qi, L. Kong, Z. Zhou, S. Liang, F. Yang and H. Liang, Chem. Biol. Drug Des., 2015, 86, 362-369.
  32. [33]33. A. C. van Leeuwen, T. Buckle, G. Bendle, L. Vermeeren, R. V. Olmos, H. G. van de Poel and F. W. B. van Leeuwen, J. Biomed. Opt., 2011, 16, 016004.
  33. [34]34. M. Deng, L. Zhang, Y. Jiang and M. Liu, Angew. Chem., Int. Ed., 2016, 55, 15062-15066.
  34. [35]35. T. Lin, P. Zhao, Y. Jiang, Y. Tang, H. Jin, Z. Pan, H. He, V. C. Yang and Y. Huang, ACS Nano, 2016, 10, 9999-10012.
  35. [36]36. I. Altintas, R. Heukers, R. van der Meel, M. Lacombe, M. Amidi, P. M. P. V. B. E. Henegouwen, W. E. Hennink, R. M. Schiffelers and R. J. Kok, J. Controlled Release, 2013, 165, 110-118.
  36. [37]37. B. Escudier and M. Gore, Drugs R&D, 2011, 11, 113-126.
  37. [38]38. S. Du Four, S. K. Maenhout, D. Benteyn, B. De Keers- maecker, J. Duerinck, K. Thielemans, B. Neyns and J. L. Aerts, Cancer Immunol. Immunother., 2016, 65, 727-740.
  38. [39]39. C. L. Peng, H. C. Lin, W. L. Chiang, Y. H. Shih, P. F. Chiang, T. Y. Luo, C. C. Cheng and M. J. Shieh, Photodiagn. Photodyn. Ther., 2018, 23, 111-118.
  39. [40]40. H. Min, J. Wang, Y. Qi, Y. Zhang, X. Han, Y. Xu, J. Xu, Y. Li, L. Chen, K. Cheng, G. Liu, N. Yang, Y. Li and G. Nie, Adv. Mater., 2019, 31, 1808200.
  40. [41]41. S. Du Four, S. K. Maenhout, K. De Pierre, D. Renmans, S. P. Niclou, K. Thielemans, B. Neyns and J. L. Aerts, OncoImmunology, 2015, 4, e998107.
  41. [42]42. D. H. Munn, M. Zhou, J. T. Attwood, I. Bondarev, S. J. Conway, B. Marshall, C. Brown and A. L. Mellor, Science, 1998, 281, 1191-1193.
  42. [43]43. D. H. Munn, E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine and A. L. Mellor, J. Exp. Med., 1999, 189, 1363-1372.
  43. [44]44. D. H. Munn and A. L. Mellor, J. Clin. Invest., 2007, 117, 1147-1154.
  44. [45]45. J. Park, B. Sun and Y. Yeo, J. Controlled Release, 2017, 263, 90-101.
  45. [46]46. B. Hoang, M. J. Ernsting, A. Roy, M. Murakami, E. Undzys and S. D. Li, Biomaterials, 2015, 59, 66-76.
  46. [47]47. C. Neuzillet, A. Tijeras-Raballand, J. Cros, S. Faivre, P. Hammel and E. Raymond, Cancer Metastasis Rev., 2013, 32, 585-602.
  47. [48]48. C. Zhou, X. Song, C. Guo, Y. Tan, J. Zhao, Q. Yang, D. Chen, T. Tan, X. Sun, T. Gong and Z. Zhang, ACS Appl. Mater. Interfaces, 2019, 11, 42534-42548.
  48. [49]49. M. Zhang, T. W. Herion, C. Timke, N. Han, K. Hauser, K. J. Weber, P. Peschke, U. Wirkner, M. Lahn and P. E. Huber, Neoplasia, 2011, 13, 537-549.
  49. [50]50. Q. Xu, J. Gu, Y. Lv, J. Yuan, N. Yang, J. Chen, C. Wang, X. Hou, X. Jia, L. Feng and G. Yin, Oncol. Lett., 2018, 15, 3437-3446.
  50. [51]51. W. J. Fu, J. Zhuo and L. K. Hu, Oncol. Lett., 2017, 13, 196-200.
  51. [52]52. Z. Liu and X. Chen, Chem. Soc. Rev., 2016, 45, 1432-1456.
  52. [53]53. L. N. Guttlein, L. G. Benedetti, C. Fresno, R. G. Spallanzani, S. F. Mansilla, C. Rotondaro, X. L. Raffo Iraolagoitia, E. Salvatierra, A. I. Bravo, E. A. Fernandez, V. Gottifredi, N. W. Zwirner, A. S. Llera and O. L. Podhajcer, Mol. Cancer Res., 2017, 15, 304-316.
  53. [54]54. Q. Chen, L. Xu, C. Liang, C. Wang, R. Peng and Z. Liu, Nat. Commun., 2016, 7, 13193.
  54. [55]55. K. Shitara and H. Nishikawa, Ann. N. Y. Acad. Sci., 2018, 1417, 104-115.
  55. [56]56. J. Kim and J. S. Bae, Mediators Inflammation, 2016, 2016, 6058147.
  56. [57]57. J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. T. Liu, B. Pulendran and K. Palucka, Annu. Rev. Immunol., 2000, 18, 767-811.

Cited by

Sorted by citations

Related

Authors
Zhou, Y., Ren, X., Hou, Z., Wang, N., Jiang, Y., & Luan, Y.
Affiliations
  • Shandong University (CN)
  • Shandong Normal University (CN)
Corresponding author
Luan, Yuxia
ORCID
Venue
Nanoscale Horizons
Publisher
Royal Society of Chemistry (RSC)
Published
2021
Volume
6
Issue
2
Pages
120-131
ISSN
  • 2055-6756 (ISSN-L)
  • 2055-6764
DOI
10.1039/d0nh00480d
OpenAlex
W3096710313
Semantic Scholar
6f05e41392dfed5a8898ef36c85ba29fc50db0c8
Cited by
165
References
58
Citations by year
2026: 4 · 2025: 26 · 2024: 27 · 2023: 44 · 2022: 25 · 2021: 38 · 2020: 1
FWCI
8.48
Type
journal article
Language
en
Open access
Licence
rsc.li/journals-terms-of-use (am, 303 d)
Locations
  • Nanoscale Horizons (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (21872083, 81903558)
  • Shandong University
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
photodynamic immunotherapy, chlorin e6, axitinib, tumor microenvironment, tumor hypoxia, vascular endothelial growth factor, indoleamine 2,3-dioxygenase inhibition, immunosuppression, reactive oxygen species, immunogenic cell death, metastasis
MeSH terms
Axitinib, Animals, Antineoplastic Agents, Chlorophyllides, Dendritic Cells, Enzyme Inhibitors, Female, Immunity, Immunotherapy, Light, Mice, Inbred C57BL, Neoplasms, Photochemotherapy, Porphyrins, Tryptophan, Photosensitizing Agents, Protein Kinase Inhibitors, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice, Nanoparticles, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review